Intravenous Tissue Plasminogen Activator Can Be Safely Given without Complete Blood Count Results Back

PLoS One. 2015 Jul 6;10(7):e0131234. doi: 10.1371/journal.pone.0131234. eCollection 2015.

Abstract

Introduction: It is well known that the efficacy of intravenous (i.v.) tissue plasminogen activator (tPA) is time-dependent when used to treat patients with acute ischemic strokes.

Aim: Our study examines the safety issue of giving IV tPA without complete blood count (CBC) resulted.

Materials and methods: This is a retrospective observational study by examining the database from Huashan Hospital in China and OSF/INI Comprehensive Stroke Center in United States. Patient data collected included demographics, occurrence of symptomatic intracranial hemorrhage, door to needle intervals, National Institute of Health Stroke Scale scores on admission, CBC results on admission and follow-up modified Rankin Scale scores. Linear regression and multivariable logistic regression analysis were used to identify factors that would have an impact on door-to-needle intervals.

Results: Our study included 120 patients from Huashan Hospital and 123 patients from INI. Among them, 36 in Huashan Hospital and 51 in INI received i.v. tPA prior to their CBC resulted. Normal platelet count was found in 98.8% patients after tPA was given. One patient had thrombocytopenia but no hemorrhagic event. A significantly shorter door to needle interval (DTN) was found in the group without CBC resulted. There was also a difference in treatment interval between the two hospitals. Door to needle intervals had a strong correlation to onset to treatment intervals and NIHSS scores on admission.

Conclusion: In patients presented with acute ischemic stroke, the risk of developing hemorrhagic event is low if i.v. tPA is given before CBC has resulted. The door to needle intervals can be significantly reduced.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous / methods
  • Aged
  • Blood Cell Count / methods
  • Blood Cells / drug effects*
  • Blood Platelets / drug effects
  • Brain Ischemia / drug therapy
  • China
  • Female
  • Humans
  • Intracranial Hemorrhages / drug therapy
  • Male
  • Platelet Count / methods
  • Retrospective Studies
  • Risk Factors
  • Stroke / drug therapy
  • Thrombolytic Therapy / methods
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage*
  • Treatment Outcome

Substances

  • PLAT protein, human
  • Tissue Plasminogen Activator

Grants and funding

Grant Support: Science and Technology Commission of Shanghai Municipality, China 1241119a8100 (X.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.